Biomaterials Research (생체재료학회지)

Korean Society for Biomaterials (한국생체재료학회)
권호 표지
DOI QR코드

DOI QR Code

Liposomal delivery systems for intestinal lymphatic drug transport

  • Ahn, Hyeji (Department of Bio and Brain Engineering, and Institute of Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST)) ;
  • Park, Ji-Ho (Department of Bio and Brain Engineering, and Institute of Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST))
  • Received : 2016.07.22
  • Accepted : 2016.11.09
  • Published : 2016.12.01
⟨ Previous Next ⟩

Abstract

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

Keywords

Acknowledgement

Supported by : KAIST

References

  1. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Disc. 2003;2:289-95. https://doi.org/10.1038/nrd1067
  2. Charman WNA, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34:175-8. https://doi.org/10.1016/0378-5173(86)90027-X
  3. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Disc. 2007;6: 231-48. https://doi.org/10.1038/nrd2197
  4. Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8: 2733-44.
  5. Wasan KM, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Disc. 2008;7:84-99. https://doi.org/10.1038/nrd2353
  6. Trevaskis NL, et al. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Disc. 2015;14:781-803. https://doi.org/10.1038/nrd4608
  7. Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Disc. 2004;3:695-710. https://doi.org/10.1038/nrd1469
  8. Porter CJH, et al. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50:61-80. https://doi.org/10.1016/S0169-409X(01)00151-X
  9. Redgrave TG. Chylomicron metabolism. Biochem Soc Trans. 2004;32:79-82. https://doi.org/10.1042/bst0320079
  10. Khoo S-M, et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90:1599-607. https://doi.org/10.1002/jps.1110
  11. Murakami M, et al. Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route. Sci Rep. 2015;5:1-13.
  12. Zhou C, et al. The preparation of a complex of insulin-phospholipids and their interaction mechanism. J Pept Sci. 2012;18:541-8. https://doi.org/10.1002/psc.2423
  13. Fricker G, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharma Res. 2010;27:1469-86. https://doi.org/10.1007/s11095-010-0130-x
  14. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-Some emerging concepts. J Pharm Sci. 2000;89:967-78. https://doi.org/10.1002/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO;2-R
  15. Dahan A, et al. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release. 2008;126:1-9. https://doi.org/10.1016/j.jconrel.2007.10.025
  16. Khan MSY, Akhter M. Glyceride derivatives as potential prodrugs: synthesis, biological activit y and kinetic studies of glyceride derivatives of mefenamic acid. Pharmazie. 2005;60:110-4.
  17. Caliph SM, et al. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats. J Pharm Sci. 2000;89:1073-84. https://doi.org/10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V
  18. Attili-Qadri S, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A. 2013;110:17498-503. https://doi.org/10.1073/pnas.1313839110
  19. Fang G, et al. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5:437-96447.
  20. Paliwal R, et al. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. J Pharm. 2009;29:181-8.
  21. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Disc. 2005;5:145-60.
  22. Yoo J-W, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Disc. 2011;10:521-35. https://doi.org/10.1038/nrd3499
  23. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36-48. https://doi.org/10.1016/j.addr.2012.09.037
  24. Andar AU, et al. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm Res. 2014;31:401-13. https://doi.org/10.1007/s11095-013-1171-8
  25. Kim H, et al. Liposomal formulations for enhanced lymphatic drug delivery. Asian J Pharm Sci. 2013;8:96-103. https://doi.org/10.1016/j.ajps.2013.07.012
  26. Iwanaga K, et al. Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int J Pharm. 1997;157:73-80. https://doi.org/10.1016/S0378-5173(97)00237-8
  27. Kisel MA, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 2001;216:105-14. https://doi.org/10.1016/S0378-5173(01)00579-8
  28. Ling SSN, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm. 2006; 32:335-45. https://doi.org/10.1080/03639040500519102
  29. Niu M, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81:265-72. https://doi.org/10.1016/j.ejpb.2012.02.009
  30. Niu M, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: A mechanistic study. Int J Pharm. 2014;460:119-30. https://doi.org/10.1016/j.ijpharm.2013.11.028
  31. Huang Y-B, et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J Drug Target. 2011;19:709-18. https://doi.org/10.3109/1061186X.2010.551402
  32. Li X, et al. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int J Nanomedicine. 2011;6:3151-62.
  33. Takeuchi H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release. 2003;86:235-42. https://doi.org/10.1016/S0168-3659(02)00411-X
  34. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117-26. https://doi.org/10.1016/S0169-409X(01)00231-9
  35. Takeuchi H, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res. 1996;13:896-901. https://doi.org/10.1023/A:1016009313548
  36. Kim HJ, Lee CM, Lee YB, et al. Preparation and mucoadhesive test of CSAloaded liposomes with different characteristics for the intestinal lymphatic delivery. Biotechnol Bioprocess Eng. 2005;10:516-21. https://doi.org/10.1007/BF02932287

Cited by

  1. Update December 2016 vol.14, pp.4, 2016, https://doi.org/10.1089/lrb.2016.29016.fb
  2. Absorption, metabolism, distribution and faecal excretion of B-type procyanidin oligomers in mice after a single oral administration of black soybean seed coat extract vol.9, pp.10, 2016, https://doi.org/10.1039/c8fo00852c
  3. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs vol.15, pp.8, 2018, https://doi.org/10.1080/17425247.2018.1503249
  4. Biodistribution of Liposome-Encapsulated Bacteriophages and Their Transcytosis During Oral Phage Therapy vol.10, pp.None, 2016, https://doi.org/10.3389/fmicb.2019.00689
  5. Lymphatic Vasculature in Energy Homeostasis and Obesity vol.11, pp.None, 2016, https://doi.org/10.3389/fphys.2020.00003
  6. The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development vol.60, pp.suppl1, 2016, https://doi.org/10.1002/jcph.1715
  7. Poloxamer-188 and D -α-Tocopheryl Polyethylene Glycol Succinate (TPGS-1000) Mixed Micelles Integrated Orodispersible Sublingual Films to Improve Oral Bioavailability of Ebastine; vol.13, pp.1, 2016, https://doi.org/10.3390/pharmaceutics13010054
  8. Advances in Oral Drug Delivery vol.12, pp.None, 2016, https://doi.org/10.3389/fphar.2021.618411
  9. Automated PET-RAFT Polymerization toward Pharmaceutical Amorphous Solid Dispersion Development vol.3, pp.3, 2021, https://doi.org/10.1021/acsapm.0c01376
  10. Recent Advancements in Polymer/Liposome Assembly for Drug Delivery: From Surface Modifications to Hybrid Vesicles vol.13, pp.7, 2021, https://doi.org/10.3390/polym13071027
  11. Comparison of nanoparticle-selenium, selenium-enriched yeast and sodium selenite on the alleviation of cadmium-induced inflammation via NF-kB/IκB pathway in heart vol.773, pp.None, 2016, https://doi.org/10.1016/j.scitotenv.2021.145442
  12. Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances vol.9, pp.24, 2016, https://doi.org/10.1039/d1tb00126d
  13. Engineering Nano‐ and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport vol.33, pp.51, 2016, https://doi.org/10.1002/adma.202104139
  14. Lymphatic transport system to circumvent hepatic metabolism for oral delivery of lipid-based nanocarriers vol.66, pp.None, 2016, https://doi.org/10.1016/j.jddst.2021.102934